Jeffrey Feike
Geen lopende functies
Vermogen: 494 505 $ op 30-04-2024
Actieve functies van Jeffrey Feike
Bedrijven | Functie | Begin | Einde |
---|
Loopbaan van Jeffrey Feike
Eerdere bekende functies van Jeffrey Feike
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Tevogen Bio, Inc.
Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Directeur/Bestuurslid | 17-08-2022 | - |
Corporate Officer/Principal | 17-08-2022 | - |
Opleiding van Jeffrey Feike
Tulane University (Louisiana) | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 3 |
Operationeel
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Tevogen Bio, Inc.
Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Beurs
- Insiders
- Jeffrey Feike
- Ervaring